Loading quotes...

Forecast

Buy	1
Hold	0
Sell	0

News Go to news feed

economic and financial calendar for 14 October with Lonza

Numerous corporate results and events are scheduled for 14 October: Lonza will report Q3 revenue, ASML and several US banks including Blackrock, Bank of America, Morgan Stanley and State Street will publish Q3 figures. There are also pre-close calls from Airbus and Schaeffler, plus other company and investor appointments. On the economic front, China's trade balance, US consumer prices and the Fed's Beige Book will be released; additionally, the Bundestag plans a government statement by Chancellor Friedrich Merz. » More on finanzen.net
Lonza starts cooperation with Asimov for scalable manufacturing of lentiviral vectors

Lonza and US company Asimov agree a strategic collaboration to advance production of lentiviral vectors for in‑vivo applications. Asimov contributes cell line technologies; Lonza provides process development, upscaling, analytics and GMP manufacturing. The aim is to develop stable production systems and to optimize genetic sequences and processes up to clinical and commercial production. Lonza shares rose briefly in SIX trading. » More on finanzen.net
Lonza advances aseptic spray drying for high‑dose subcutaneous therapies

Lonza is developing an aseptic spray drying process at its Bend (USA) site to enable high‑concentration formulations of biologics such as monoclonal antibodies, antibody‑drug conjugates (ADCs) and peptides. Initial tests showed various antibodies and ADCs can be reliably spray dried, with the aim of creating new solutions for high‑dose subcutaneous applications. The process is intended to improve stability and reduce viscosity but still faces technical hurdles such as protein stability, sterile processing, formulation optimization and scaling to industrial production. The Lonza share was at times 0.64% lower at 571.53 francs. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, LONZA has already paid €5.47 in dividends. The last payout was in May.

Financials

In the last quarter, LONZA had revenue of €3.66B and net profit of €640.26M

(EUR)	June 2026	YoY
Revenue	3.66B	-
Gross profit	1.4B	-
Net profit	640.26M	-
EBITDA	1.24B	-

Fundamentals

Metric	Value
Market capitalization	€47.79B
Number of shares	69.84M
52-week high/low	€688.51 - €333.91
Dividend yield	0.80%
Dividends TTM	€5.47
Beta	0.84
P/E ratio	-410.52
PEG ratio	2.56
P/B ratio	5.44
P/S ratio	6.98

Company profile

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.